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Palavras-chave 
 
resumo 
 
 
 
Investigação clínica, Redes de investigação clínica 
 
O tema da tese são as redes de investigação clínica 
Europeias e o seu impacto na investigação clínica e no 
desenvolvimento de novos medicamentos e terapias. 
  
A tese apresenta o produto final de uma recolha exaustiva 
de informação sobre redes de investigação clínica existentes 
na Europa de forma a caracterizar o perfil atual destas redes 
na Europa. É também avaliado o seu impacto através da 
descrição das principais atividades dessas redes. 
Finalmente assinalam-se iniciativas que poderão potenciar a 
contribuição destas redes para uma investigação clínica 
mais efetiva na Europa.  
 
A pesquisa foi realizada através da Internet entre dezembro 
de 2013 e maio de 2014, uma vez que um website é uma 
ferramenta essencial para o funcionamento de organizações 
desta natureza. Assim, partiu-se da premissa de que o 
número de websites de redes de investigação clínica 
existentes na Internet corresponde ao número de redes de 
investigação clínica efetivamente existente. 
 
Não foi identificada nenhuma fonte que reunisse informação 
ou listagens referentes a redes de investigação clínica na 
Europa. Verificou-se ainda a existência de bastante 
informação na Internet, mas que esta se encontra dispersa 
de um modo aleatório na Internet e na maioria dos websites 
a informação não está muito trabalhada, o que incrementou 
o desafio desta recolha.  
 
Uma vez que pesquisa se focou na região da Europa, o 
ponto de partida desta pesquisa foi o website da Agência 
Europeia do Medicamento, EMA. 
 
Nesta tese apresentam-se os critérios definidos para a 
classificação de redes de investigação clínica, bem como os 
dados recolhidos sistematicamente de cada uma das redes. 
É feita ainda uma caracterização descritiva do conjunto das 
redes europeias de investigação clínica, a partir da qual se 
parte para uma discussão dos pontos fortes e pontes fracos. 
Finalmente, são apresentadas conclusões, perspetivas para 
o futuro e potenciais formas de otimizar/ maximizar a 
performance das redes europeias de investigação clínica. 
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The theme of the thesis is the European clinical research 
networks and their impact on clinical research and on the 
development of new drugs and therapies. 
 
This report presents the final product of an exhaustive search 
about clinical research networks in Europe in order to 
characterize the profile of these networks in this region. It is 
also assessed its impact by describing the main relevant 
activities of these organisations. Finally, a few initiatives that 
may increase the contribution of these networks for a more 
effective clinical research are suggested.  
 
The search was performed in the Internet between december 
2013 and may 2014, as websites are an essential tool for 
organizations of this nature. Therefore, it was assumed that 
the number of websites of clinical research networks 
corresponds to the number of clinical research networks that 
exists effectively.  
 
It was not identified any source that gathered information or 
that listed clinical research networks in Europe. It was also 
verified that there are much information in the Internet, but 
information is dispersed and in the majority of the websites 
the information is not very well processed, which increases 
the challenge of this search.  
 
This search was focused in Europe, thus the starting point of 
the search was the website of the European Medicines 
Agency, EMA. 
 
The thesis presents the criteria that were defined to classify 
the organizations as clinical research networks and the data 
collected from each identified clinical research network. It is 
also done a descriptive characterization of the clinical 
research networks to assess the strengths and weaknesses. 
Finally, conclusions, suggestions for the future and strategies 
to optimize/ maximize the performance of the clinical 
research networks are presented. 
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Networking requires know-how and expertise, but also team spirit, team 
players, shared goals, natural trust and confidence.(1) 
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ICRIN Irish Clinical Research Infrastructure Network  
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IMI The Innovative Medicines Initiative 
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IRCI International Rare Cancers Initiative 
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1. Introduction 
 
1.1. General Introduction 
 
This report was written as part of the Master’s degree in Pharmaceutical 
Medicine and it presents the information about the search of the existing 
European clinical research networks that was performed between december 
2013 and may 2014. 
The document is composed by 4 main sections: Introduction, Methodology, 
Results and Discussion and Conclusion. 
The first section, Introduction, is divided into two main parts: 1) a brief status of 
clinical research in Europe and 2) networking in clinical research. In the first part 
it is described the aim of clinical research, the European clinical research 
landscape, the integration of the European clinical research in the world 
context, the economic impact of clinical research and finally the challenges of 
clinical research. In the second part it is described the definition and objectives 
of networking in clinical research, the history of the first clinical research 
network, the EORTC, and finally the rationale of this thesis. 
Section 2, Methodology, describes how the search was conducted by 
presenting the main steps performed to do the search of the European clinical 
research networks and the criteria that were defined to classify an organisation 
as a clinical research network. 
Afterwards, Section 3, Results and Discussion, presents the results of the 
search and the corresponding discussion. 
Finally, Section 4, Conclusion, presents the main conclusions about the search 
and about the results obtained. It is also mentioned in this final section, actions 
to maximize the contribution of the European clinical research networks to the 
clinical research and to the development of new drugs and therapies. 
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 1.2. Brief Status of clinical research in Europe – the maze   
 
1.2.1. The aim of clinical research 
 
Biomedical research is divided into basic, clinical and translational research. Basic 
research is a systematic study directed toward greater knowledge or 
understanding of the fundamental aspects of phenomena. Translational research 
was created to accelerate the transfer of knowledge from basic to clinical research 
(2). Clinical research plays an important role in understanding better the diseases, 
in the development of new health products (preventive, diagnostic and therapeutic) 
and in the optimisation of medical strategies as it produces evidence-based 
practice and healthcare cost containment. Thus, the main goal of clinical research 
is to obtain treatment, prevention and diagnosis of diseases. To succeed in clinical 
research it is necessary an easy access to patients and to overcome the 
fragmentation of the different national health and legislative systems and the 
difficulties of obtaining funding (especially for academic studies)(3). Appropriate 
funding and best practice for medical research are key factors to improve 
healthcare and also economy (2).  
 
1.2.2. European clinical research landscape 
 
Clinical research has had a great impact on society. In the last 40 years, infant 
mortality has decreased significantly. In terms of adults, new medicines have 
revolutionised the treatment of many diseases such as, heart attacks, high blood 
pressure and acquired immunodeficiency syndrome (AIDS). Many fatal diseases 
are no longer life-threatening due to advances in medicine. In fact, death rates in 
Europe have fallen for all main causes of death (2). 
 
Still, Europe is facing the grand challenges such as global warming; tightening 
supplies of energy, water and food; ageing societies; unequal public health; allergy 
and chronic diseases; cancer and cardiac diseases; pandemics and security that 
are changing the disease patterns and increasing the need of more medical 
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research (4). To address all these challenges, clinical research has to be prepared 
and well-organised. Therefore, a strong scientific environment and good quality 
research infrastructures are essential. Researchers’ mobility, partnerships and 
motivation are key points in this environment (2). 
 
The positive point is that medicine is advancing rapidly. For example, genome 
sequencing is almost a routine that can be useful in supporting individual 
treatment as many genetic variations have been related to an increased risk of 
disease (e.g. heart diseases, stroke, diabetes, dementia and cancer). Stem cell 
technology is also advancing and it is being used to replace damaged cells and 
tissues. Further, innovation in information technology is producing powerful new 
imaging, diagnostic techniques and almost infinitive data store. For example, 
storage of data was until recently measured in terabytes and now it is measured in 
tens of petabytes and it will definitely increase a further million-fold by 2020 (2). At 
the same time, medical research is turning into a demanding multidisciplinary area 
due to the improved computational power, the increased results in disciplines of 
the basic science such as human genomics (5). 
 
It should also be highlighted that the study of the social, economic and 
environmental factors that influence health is as important as the genetic and 
biologic factors. For example, it is widely accepted that a poor diet, tobacco, 
alcohol and lack of physical exercise may have a negative impact in health. To 
improve lifestyles and habits it is needed the engagement and good coordination 
among all stakeholders of the society (2). 
 
Europe has a variety of world-leading researchers, higher education institutions, 
public research organisations, public universities and public university hospitals 
with excellent and recognised health professionals. European countries have also 
well organised and well equipped healthcare systems widely accessed by the 
population and a great number of university hospitals with high level of healthcare. 
Finally, history has proved that Europe is able to face complex challenges (2). 
Nevertheless, the variety of national clinical research strategies may be a 
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weakness. Moreover, 84% of the public funding in Europe is concentrated in a few 
countries. Therefore, European clinical research is considered heterogeneous and 
disparate. Europe has a number of major clusters that are strong, competitive, 
visible and attractive. Thus, Europe should align all its potential(2). 
 
Another negative aspect is the fact that the mobility of researchers and ideas are 
limited by the different national regulatory frameworks, by the lack of 
harmonisation policies that leads to different ways of implementing the European 
Union (EU) Directives and by the gaps in the legislation (2). An exception is the 
case of Sweden, Norway and Denmark that are independent countries that have 
similar legislation that facilitates collaboration among them. Clinical research 
network can improve the efficiency of the clinical research by creating 
communication between the different institutions and planning strategies for 
clinical research development (4).  
To fight against the limiting factors in Europe, large research infrastructures are 
another way of increasing European competitiveness in clinical research as they 
create scientific communities across Europe. These communities facilitate the 
researchers’ mobility and training (2).  
 
In fact, the Member States (MS) of the European Union share the same European 
Directives to elaborate their national laws. Nevertheless, due to the different 
interpretations, a complete harmonization among the MS is never achieved, 
turning the conduct of multinational clinical trials into a complex mission for the 
pharmaceutical industry and academy (6).  
 
The “Eurocan plus report”, a feasibility study for coordination of national cancer 
research activities in Europe, can be extrapolated for European clinical research in 
general. This report concluded that fragmentation and lack of sustainability are the 
two main challenges that clinical research faces in Europe. This fragmentation 
leads to duplication of clinical research work that consequently leads to avoidable 
waste of time and money that could be used in other projects. There is also lack of 
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communication between the stakeholders, namely, funders and researchers. 
Other relevant disadvantages identified in Europe are: 
1) the shortage of leadership; 
2) the fact that each institution has its own agenda lacking a global vision; 
3) lack of functional contact between academy and industry; 
 4) inadequate training and non-existent career paths; 
5) low personnel mobility in research; 
6) lack of functional translational research continuum process; 
7) lack of epidemiological research integrated with clinical research; 
8) lack of functional information flow; 
9) lack of efficient funding (e.g. difficulty in obtaining long-term financing, grants 
are usually slow to be obtained) 
10) lack of efficient networking (7).   
 
It should also be noticed that society is not involved as much as advisable in the 
clinical research issues. Many people consider that patients are not considered in 
the centre of clinical research. Moreover, it is not only the interpretation of the 
European Directives that differs from Member State to Member State. In fact, 
Europe is not a homogenous area; the different countries have different cultures, 
habits and legislations. Further, there is not a common plan in clinical research 
neither harmonisation in what concerns approvals, evaluation, assessment, 
education and training. Europe also lacks clinical research career tracks, mobility 
for investigators and a common educational programme. It should be highlighted 
that medical research has never been considered as important as it is nowadays, 
playing a key role in health of society. Further, the unmet medical needs are 
creating new complex challenges and new paradigms such as personalized 
medicine. The economic models of the pharmaceutical industry are also shifting 
and the first large scale initiatives of partnerships between academia and industry 
are showing relevant results. Finally, Europe has to learn how to take advantage 
of its diversity (2). 
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It is a fact that Europe has excellent basic, clinical and innovative etiological 
research that should be better explored. While, Phase III clinical trials are 
migrating to Asia, clinical trials of Phase I and Phase II remain in Europe due to 
the unique expertise. This region also detains important and unique biobanking 
resources (7).  
 
The European Science Foundation in a report on the European Biomedical 
Research, White Paper II, gives 5 main recommendations regarding the future of 
the European biomedical research, as follows: 
1 - “Citizens and patients should be closely engaged with biomedical research.” 
2 - “The results of biomedical research should be rapidly and efficiently brought to 
the patient.” 
3 – "Biomedical research should be conducted with high quality in an open, 
honest and transparent way.” 
4 – “European biomedical research should be conducted within a global context.” 
5 – “Investment should be increased to create the right world-class biomedical 
research. (2)”  
 
1.2.3. Clinical research: Europe versus the rest of the World 
 
As previously mentioned, Europe is widely known of being an “excellence in 
science”. The European investigators and the health universities are worldwide 
recognised (2). Biomedical research generates about half of the European 
scientific publications. At the moment the United States of America (USA) have 
higher funding than Europe does (funding in Europe is about half of the USA 
funding (2), being consequently the clinical research output lower in Europe than 
in the USA. Since the 1990, USA has replaced Europe in the top of the developers 
of medicines (2). Nevertheless, the number of publications in Europe is greater 
than in the USA (2). Thus, it can be concluded that Europe presents a very 
efficient biomedical research with a strong and large health industry in spite of a 
lower funding than in the USA (2).  
 25 
 
In terms of publishing, USA and EU together produce almost 2 thirds of the world 
publishing. This world share tends to decrease due the emerging countries such 
as Brazil, China and India (2).  
 
In fact, geopolitical is changing as new powerful economies are growing (e.g., 
China, India and Brazil). Many of the scientists of these countries are studying in 
the USA what contributes to the creation of stronger links with the USA rather than 
with Europe (2). 
To summarize, the major threats to European clinical research are the USA that 
has greater funding than Europe and the emerging countries such as India, China, 
Brazil. This can cause a loss of attractiveness and leadership of Europe in the 
industry perspective. Consequently, there is the threat of potential increase of the 
European healthcare costs. Therefore, Europe has to create a single science 
policy involving all stakeholders, society, academia and industry (small and large 
enterprises) to be able to influence the global healthcare to improve the quality of 
life of the European and world citizens (2).  
 
Although globalisation increases competition, as it was previously described, at 
the same time it opens great opportunities for international partnerships. Global 
collaboration is becoming fundamental to overcome the great challenges (2).  
 
1.2.4. The economic impact of clinical research 
 
Clinical research presents a positive economic return due to the health gains and 
commercial gains. To assess the economic impact of medical research it is 
necessary a complex calculation with limitations due to the assumptions that are 
needed. Therefore, the studies are scarce. A study in the USA concluded that 
investment on medical research returns many times over in social benefits. 
Nevertheless, Europe has a different reality and results cannot be extrapolated. 
The existing European studies do not have an adequate approach of the issue of 
economic research. The results of the investment on medical research should be 
considered essential to choose the best strategies for the future of medical 
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research (5). Therefore, the economic impact of clinical research in Europe should 
be assessed. Clinical research networks may help in this area, as they can gather 
data from the different member institutions. 
 
1.2.5. Clinical research global challenges  
 
Despite the increase of investment in Research & Development (R&D), the 
productivity of the big pharmaceutical companies is decreasing and a significant 
number of patents is expiring. At the same time, the biotech companies that are 
creating new drugs have difficulties in obtaining partners for funding due to the 
high cost and high risk of R&D. 
One of the challenges of clinical research is the translation of the biomedical 
discoveries into new drugs and therapies. Moreover, regulatory authorities are 
changing the approaches to assess benefit-risk profiles and patients are willing to 
be part of the stakeholders in the healthcare sector. 
Further, the present crisis imposes the cut of investments, increasing the 
challenge of obtaining new drugs. 
 
All the described challenges that clinical research is facing influence directly the 
pharmaceutical industry. The major challenges of the industry are: 
- Complexity and quantity of data are increasing; 
- There is a move towards the 4P medicine: personalised, predictive, 
preventative and participatory; 
- The number of market approvals are decreasing and R&D costs continue to 
increase; 
- The emergence of the generic medicines; 
- The need to enhance anticipation and minimisation of risk within the 
industry; 
These challenges pushed the industry to establish relationships with academy, 
biotechs, small and medium enterprises and even with multinational companies. 
Pharmacy industry understands that in-house research is not enough for the 
success (2).  
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In fact, collaborations between industry, academia, regulatory authorities and 
patients’ organisations are seen more and more the key factor for the success of 
obtaining new drugs. One significant example in Europe is The Innovative 
Medicines Initiative (IMI) that is a European public-private partnership between the 
European Commission (EC) and the European Federation of Pharmaceutical 
Industries and Associations (EFPIA) that started in 2008 to improve the 
competitiveness of the pharmaceutical industry in Europe. It has 46 projects on-
going with a budget of €2 billion between 2008 and 2013 and a budget of €3.3 
billion between 2014 and 2024 (8, 9). Although this type of initiatives is more than 
welcome, it is also essential that these initiatives are not limited in time to avoid 
the fragmentation by projects. Well established networks are a fruitful option as 
know-how and data is accumulated from project to project.    
 
Another weakness in Europe is the low number of academic studies and 
multinational academic studies. In fact, less than 10% of the Investigator Driven 
Clinical Trials (IDCT) are multinational, whereas in the case of the commercial 
clinical trials, about 50% are multinational. IDCT are clinical trials whose sponsors 
are academic researchers and, like in the industry-driven clinical trials, the aim is 
to obtain scientific knowledge and evidence about a drug, therapy or about the 
disease. Usually these studies have not commercial interest. Some examples are: 
proof of concept studies, studies on orphan diseases, comparison of diagnostics 
or therapeutic interventions, surgical therapies or novel indications for registered 
drugs. IDCT have an important role in terms of patient-oriented clinical research, 
being the basis for continually improving patient care. In a conference organized 
by the European Science Foundation in 2008 while discussing the reasons for the 
reduced number of IDCT in Europe, a vast number of recommendations were 
produced, such as: 
1. Scientists who participate in IDCTs should have access to better education, 
training, career structure and opportunities; 
2. Funding for IDCT should be increased; 
3. Regulation of IDCT should have a specific “risk-based” approach; 
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4. The procedures for obtaining authorization for IDCT should be streamlined; 
5. It should be ensured that IDCT have the adequate number of subjects to obtain 
statistically reliable results; 
6. IDCT are an advantage for the society that will have access to improved 
patient care and also for the industry with the transfer of scientific innovation 
from the laboratory to the bedside. 
Efficient IDCT demand specialised competences and advanced infrastructure. 
They are performed in academic medical centres and university hospitals. 
Nevertheless, data management, quality assurance, monitoring, regulatory affairs 
are lacking in Europe for this type of trials (10). This is one of the challenges that 
clinical research networks are able to respond. 
In fact, to invert this trend of the low number of multinational IDCT, national 
networks were developed in most of the MS to increase the number of multicentre 
clinical trials and create common procedures for submission and conduction of the 
clinical trials, focusing in IDCT. The European Clinical Research Infrastructures 
Network (ECRIN) was created in 2004, it was funded by the FP6 Health and it is a 
net of national networks. This network aims to overcome the fragmentation of 
health and legislative system in Europe by providing information, consulting, 
coordination, management and other services to investigators and sponsors in the 
preparation and conduct of multinational clinical trials with focus in IDCT. The final 
goal is to create a common pan-European culture among clinical research 
professionals by implementing common training and communication and also by 
creating common procedures and standards for investigation in the different areas 
(11).  
 
Key message 
Although clinical research has had a great impact on drug development and 
consequently on the health of the European society, clinical research has never 
faced such a tremendous number of challenges. The most relevant are: 
1) high number of unmet medical needs; 
2) massive volume of information being produced everyday; 
3) demanding of multidisciplinary in clinical research; 
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4) heterogeneous environment of clinical research due to different regulatory 
frameworks and different cultures from country to country; 
5) high costs of clinical research; 
6) reduced productivity of the pharmaceutical industry. 
If efforts of the different stakeholders in clinical research are aligned, the 
probability of success increases exponentially. Clinical research networks can be a 
useful tool to align the different stakeholders and create a common strategy to 
optimize the productivity of the each element.  
 
1.3. Networking in clinical research 
 
1.3.1 Definition and objectives 
 
The definition of networking is: a supportive system of sharing information and 
services among individuals and groups that have a common interest. (12). 
Clinical research networks fit exactly in this definition as they are formed by 
independent groups with independent management that share a common interest 
in clinical research and that are aware that gathering expertise, know-how and 
efforts of the different members will certainly bring better and faster outcomes. It is 
now fully accepted that collaboration among individual research groups is no 
longer the solution and that solid and permanent partnerships are proving to be 
the key factor to achieve success. 
   
With the exponential growth of the scientific and technical discoveries, clinical 
research is getting more complex and is demanding expertise from many different 
fields. For instance, the discoveries in the field of genetics, epigenetics and 
genomics changed the approaches to cancer risk identification and management, 
cancer diagnosis, prognostic evaluation and therapies (13). In most of the cases it 
is not possible to gather in one single institution the know-how of all the involved 
fields of a research project, hence, networking can make the difference between 
failure and success. 
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Medical Societies were the first networks of the biomedical history. These 
academies or learned scientific societies are member organisations for physicians 
and researchers and are specialised in certain fields or disciplines. In most of the 
cases there are national societies and European-wide scientific societies. The 
latter usually have an English language peer review journal.  
 
We have been assisting to a shift in science from an individual-based model to a 
teamwork model. This is explained by the huge amount of data that is now 
possible to produce and to store due to the innovation in technology and it is also 
explained by the need of having multidisciplinary teams to face the high 
demanding of science. Moreover, sharing knowledge, techniques, equipment and 
ideas, pooling data and research resources are some of the advantages of 
networking that can lead to successful results more rapidly and with more quality. 
Nevertheless, among networks there might be miscommunication, difficulties with 
the coordination of meetings, travel expenses and disagreements in the main 
goals of research. The increase of costs should also be taken into account (14).  
 
In fact, there are a significant number of good reasons to have a networking 
approach in clinical research:  
- To contribute to the translational research from the lab to the bed of the 
patient and vice versa. (15, 16)  
- To decrease the gap between basic and clinical research and the gap 
between clinical research and implementation in real life. 
- To facilitate clinical research between academy and industry. (15, 17, 18) 
- To increase the collaboration between the elements of the network. (19, 20) 
- To develop multidisciplinary research partnership. (19) 
- To promote the collaboration between centres to guarantee infrastructure 
support, critical mass of expertise and resources such as patients and data. 
- To stimulate the creation of new networks. (19) 
- To promote high quality research, focusing on multicentre activities and 
randomized clinical trials. (15-17, 21)  
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- To study rare diseases, as recruitment can be facilitated. (16)  
- To ensure the training in clinical research, trial methodology, Good Clinical 
Practices and Good Laboratory Practices of the health professionals such 
as, medicines, pharmacists and nurses. (15, 18, 19, 22) 
- To promote education and training in specific areas of medicine, such as 
vaccinology. (20, 22)  
- To support the patients, their families and patient organisations by informing 
them about clinical research during their participation in clinical research. 
(15) 
- To be a source of information and expertise for health professionals and 
researchers. (18, 19, 22) 
- To create a forum of scientific discussion. (19) 
- To create scientific and operational quality standards and to create 
guidelines and templates to harmonise operational models. (18, 19, 22) 
- To avoid duplication of clinical trials or other studies. (19) 
- To raise awareness on the need for clinical trials that the industry is not 
interested, such as off-patent medicines and observational studies on 
natural history of diseases. (19) 
- To contribute to the compliance of GCP and advocate for ethical research. 
(19) 
- To facilitate clinical trials among different countries and to facilitate 
recruitment. (19) 
- To promote communication and information exchange between institutions. 
(20) 
- To activate cooperative projects for biological research. (16) 
- To support the study conduct in the sites that are part of the network. (22) 
- To increase scientific competitiveness. (23) 
- Optimize scientific potential and expertise. (23) 
- To increase recruitment and speed up recruitment that impact in the 
statistical power, duration of the trials, publications and also in the 
innovation for the patients. (23) 
- To attract industry. (23) 
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- To increase solid partnerships with the rest of the world. (23) 
 
As previously mentioned, networks can give an effective contribute to Europe 
to(11):  
- Play a leader role in major research and innovation challenges.  
- Develop new healthcare models (personalized and stratified medicine). 
- Address health challenges (rare diseases, ageing, health technology) 
- Translate clinical research into clinical practice. 
- Achieve health cost containment. 
- Promote evidence-based medical practice and enhance health 
- Reduce health inequalities in Europe and ensure equal access to 
healthcare. 
 
1.3.2. EORTC – the first clinical research network 
 
The European Organisation for Research and Treatment of Cancer (EORTC) is 
the oldest and the best example of success of networking in clinical research. It is 
a unique association that conducts multinational clinical trials of all types of 
cancer. It is not possible to write about clinical research networking without 
referring to EORTC. 
The goal of EORTC is to develop, conduct and motivate translational and clinical 
research in Europe to improve the health care of patients with cancer by improving 
the standard of cancer treatment. Extensive and comprehensive research is 
usually not possible by individual hospitals and can be best accomplished through 
the multidisciplinary multinational contributions of basic scientists and clinicians. 
EORTC was created in 1968 from the Groupe Européen de Chimiothérapie 
Anticancéreuse (GECA) that had been founded by Prof. Henri Tagnon in 1962. By 
that time that group of experts were already aware of the relevance of a 
multidisciplinary approach and international collaboration in clinical research in 
Europe. 
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The EORTC Network associates more than 300 hospitals in more than 30 
countries that includes about 2500 elements from the different disciplines needed 
for cancer research. The EORTC headquarters are located in Brussels, Belgium. 
Between 2000 and 2011, 71905 patients participated in clinical trials of EORTC, 
being about 90% of them from the European Union. 
The EORTC has multiple sources of funding such as the European national 
cancer leagues and the US National Cancer Institute (NCI). 
The greatest achievements of EORTC are that the clinical trials performed within 
the EORTC framework have led to increased survival rates for childhood cancers, 
Hodgkin’s disease and leukaemia, melanoma, breast, uterine, prostate, testicular 
and bladder cancers, lung and larynx cancers and other rare tumours (brain and 
sarcoma). (24) 
 
1.3.3. Rationale 
 
Considering that: 
- Clinical research is facing a significant number of challenges ant networking can 
be a key strategy to increase productivity in clinical research. 
- Networking has multiple advantages such as flexibility, convenient ways to 
share resources, lower costs, less administrative burden and easiness in 
gathering multidisciplinary teams.  
- Clinical research network can provide centralised resource and adequate 
access to patient populations for the execution of clinical trials. This is important 
to obtain adequately powered clinical trials, to facilitate the development drugs 
for orphan diseases and to enhance the medical science of the sites.  
- Well identified clinical research networks can lead to new projects among the 
stakeholders: industry, academy, regulatory authorities and society. 
- It seems that the number of clinical research networks has been increasing 
significantly in the last 2 decades. 
- There is not any systematic investigation about the existing clinical research 
networks in Europe, neither a list of the networks. 
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This project aims: 
1) to gather a full list of the existing clinical research networks working in 
Europe; 
2) to characterise the profile of the existing European clinical research 
networks; 
3) to sort out possible actions to maximize the benefits that clinical research can 
take from the clinical research networks. 
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2. Methodology 
 
2.1. Search of clinical research networks 
 
In a preliminary stage, it was conducted a search to assess whether there was 
already any project, thesis, document or website with systematic information about 
European clinical research networks. It was not identified any source with 
information regarding clinical research networks in Europe. Further, from this 
preliminary search, it was verified that the information about clinical research 
networks is almost found exclusively in the websites of the clinical research 
networks.  
 
The search of information about the existing European clinical research networks 
was performed between december 2013 and may 2014. Search was done using 
the Internet, as websites were considered an essential tool to such a type of 
organisation as a network. Therefore, search was done with the assumption that 
the number of websites of clinical research networks corresponds to the effective 
number of the existing clinical research networks.  
 
The steps of the search in the Internet were done as follows: 
1) As search was focused in the European region, the starting point of this 
search was the website of the European Medicines Agency (EMA). The 
website was carefully reviewed to identify all the names of clinical research 
networks. All the networks that were identified in the website of EMA were 
verified in the search engine of Google to obtain their websites’ links. 
2) Each website of a potential clinical research network was carefully reviewed 
and relevant information was collected.  
3)  Further, in each website of a potential clinical research network that was 
reviewed to collect data, it was kept in mind to check if there was any 
reference or link to another clinical research network. This step was very 
fruitful, as it led to the identification of a significant number of other clinical 
research networks and step 2 was repeated to these new networks.  
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4)  In order to identify as many clinical research networks as possible, the 
websites of European medical societies were reviewed to check if clinical 
research networks were mentioned in their websites and also to check if the 
medical societies had any production of clinical research. To make sure that 
as many medical societies websites as possible were reviewed, it was used 
the search engine of Google writing “society” and the various disciplines of 
medicine. In each website of the medical society, sections such as: “Clinical 
Research”, “Publications” and “Links” were carefully verified. 
5) Other searches were done in the search engine of Google, using key words 
such as: “clinical research”, “network”, “networking“, “investigator driven 
clinical trials”, etc. This search was not successful. 
6) Finally the website of the World Health Organization was carefully verified to 
identify any clinical research networks. No positive results were obtained. 
 
As the type, quantity and complexity of information released by each website differ 
widely from network to network due to the different policies, it was defined a set of 
parameters to organise the collection of data in each website: 
- Name of the clinical research network; 
- Acronym of the clinical research network; 
- Brief description of the clinical research network with the main goals; 
- National/international clinical research networks; 
- Number of members; 
- Relevant activities;  
- Website address; 
- Country; 
- Year of establishment; 
- Nature: private/public; 
- Target disease. 
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2.2. Criteria for the classification of clinical research network 
 
One of the great challenges of this search was how to decide whether an 
organisation could be considered a clinical research network or not. Therefore, it 
was essential to establish since the beginning of the search a set of criteria to 
assess whether each organisation could be considered as a clinical research 
network. 
The criteria used are as follows: 
- Headquarters in Europe or networks with headquarters outside Europe but 
with European members (search was limited to the European region); 
- Organisation with associated members (to validate the network definition); 
- Organisation with projects with undetermined time (to ensure that 
consortiums and single projects were not included in the search); 
- Evidence of production of clinical research by presenting the number of 
clinical trials and/or publications (to ensure that it is a network of clinical 
research). 
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3. Results and discussion 
 
3.1. Results 
 
Eighty-eight clinical research networks were identified in the Internet between 
december 2013 and may 2014. The identified clinical research networks are listed 
in Table 2. Table 2 presents the name, acronym, brief description, country and 
year of establishment of the networks. 
 
Almost all European countries have clinical research networks: Austria, Belgium, 
Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, 
Luxembourg, the Netherlands, Northern Ireland, Poland, Portugal, Romania, 
Scotland, Spain, Switzerland, the United Kingdom and Wales. The UK is the 
country with the highest number of clinical research networks, 11 networks, 
followed by Germany with 10 networks. Spain and Switzerland have 8 networks, 
Belgium and Italy have 7 networks and Austria, France, and the Netherlands have 
5 networks. Hungary, Ireland, Poland, Portugal, Scotland and the USA have 2 
networks. Finally, Czech Republic, Denmark, Finland, Ireland, Luxemburg, 
Northern Ireland, Norway, Romania, Sweden and Wales have 1 network. 
 
Clinical research networks were established between 1962 and 2014. The oldest 
one is the EORTC and the newest one is under construction at the moment, and it 
is the International Society of Paediatric Oncology European Neuroblastoma 
Research Network (SIOPEN-R-NET). The number of new clinical research 
networks established per decade is presented in Table 1.  
 
Table 1 – Number of new clinical research networks per decade. 
Decade Number of networks 
Before the 1980s 4  
1980s 5 
1990s 10 
2000s 42 
Between 2010 and 2014 15 
Date of establishment not available 12 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment. 
Line Name Acronym Brief description Country Year 
1 Academic Clinical Oncology and Radiobiology Research Network (25, 26) ACORRN 
The network aims to bring together all disciplines needed for 
radiotherapy and to support radiotherapy research, dissemination and 
implementation. 
UK 2005 
2 
AntiPhospholipid Syndrome Alliance for 
Clinical Trials and International Networking 
(27) 
APS ACTION 
The aim of the network is to design and conduct well-designed, large-
scale, multicentre clinical trials in persistently antiphosphilipid anti-
body (aPL)-positive patients. 
USA 2010 
3 Austrian Clinical Research Infrastructure Network (28) ATCRIN 
The network aims to provide support to biomedical research by 
facilitating non-commercial multinational trials with clinical sites in 
Austria. The network also provides training. 
Austria 2007 
4 Belgian Pediatric Drug Network - Belgian Pediatric Clinical Trial Network (29) BPDN 
The aim of the network is to place child health, rights and interest as 
the primary consideration by: enforcing good clinical practice, 
establishing a network of active units in clinical research and 
collaborating with other european networks. 
Belgium 2005 
5 Breast International Group (30) BIG 
The network aims to accelerate breast cancer research by promoting 
collaboration between its members and other academic networks. 
This network works independently of the pharmaceutical industry. 
Collaborative groups based in Europe, Canada, Latin America, Asia 
and Australia. 
Belgium 1999 
6 Central European Society for Anticancer Drug Research (31) CESAR 
The network aims to increase the cooperation between academic 
study groups, individual institutions in Oncology and pharmaceutical 
industries, fostering translation of basic research into clinical 
application via intergral drug development. CESAR as European 
Economic Interest Grouping is the umbrella organisation of the 
registered societies CESAR Germany and CESAR Austria.  
Austria 2001 
7 Centre de Recherche Public de la Santé (32) CRP-Santé 
The aim of the network is to perform clinical research studies, 
clinically-oriented biomedical research and public health.These 
activities will lead to new knowledge in disease mechanisms, 
epidemiology, diagnostics and treatment of diseases. 
Luxemburg 1988 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.1).  
Line Name Acronym Brief description Country Year 
8 Childhood Liver Tumours Strategy Group (33) SIOPEL 
The aim of the network is to promote cooperative clinical and basic 
research in the field of primary childhood liver tumours. The ultimate 
goal of the study group is to ameliorate the prognosis and the quality 
of life of children affected by this rare neoplasm. 
Poland 1987 
9 Czech Clinical Research Infrastructures Network (23) CZECRIN 
The aim of the network is to develop an infrastructure and capacity to 
facilitate clinical research primarily academic driven.  
Czech 
Republic 2011 
10 Consorzio Italiano per la Ricerca in Medicina (34)  CIRM 
The aim of the network is to establish partnerships to develop national 
and European research projects, namely, biologic, medical, non-
medical healthcare, socio-economic and biostatical areas. 
Italy 1997 
11 Danish Clinical Research Infrastructures Network (28) DCRIN 
The aim of the network is to improve the quality of clinical research at 
a national and international level by promoting harmonised research 
procedures, reducing the time with administrative procedures, sharing 
expertise. 
Denmark 2003 
12 Deutsche Chronic Lymphocytic Leukemia Study Group (35) DCLLSG 
The aim of the network is to optimize the diagnosis and treatment of 
chronic lymphocytic leukemia by performing controlled prospective 
clinical trials. 
Germany 1996 
13 Dutch Federation of University Medical Centers (36) NFU 
The aim of the network is to ensure that the bodies that decide on 
health care, education and science in the Nerherlands take into 
account the vision of this network. The network also aims to 
strengthen the research infrastructure. It is focused on biobanks, 
translational research and patient-related research. 
Netherlands 2004 
14 European Brain Injury Consortium (37) EBIC 
The aim of the network is to establish close co-operation between 
European Neurotrama Centers and Investigators in the management 
of Traumatic Brain Injury (TBI) and other types of acute brain damage 
and to act as an advisory organ in both practical and theoretical 
issues concerning brain injury studies. 
Netherlands 1994 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.2).  
Line Name Acronym Brief description Country Year 
15 European Clinical Research Infrastructures Network (23, 38) ECRIN 
Network of national clinical research networks that aims to provide 
consulting, coordination, management and all the needed services to 
investigators and sponsors in the conduction of multinational clinical 
trials. The main target are the academic sponsored clinical trials.  
France 2004 
16 European Cystic Fibrosis Clinical Trial Network (22) ECFS-CTN 
The aim of the network is to increase the quality and quantity of 
clinical research in the area of cystic fibrosis and to bring new 
medicines to the patients as quickly as possible. 
Belgium 2009 
17 European Group for Blood and Marrow Transplantation (39) EBMT 
The aim of the network is to allow scientists and physicians involved 
in clinical bone marrow transplantation to share their experience and 
develop cooperative studies. 
UK 1974 
18 European Neonatal Network (40) EuroNeoNet 
The network aims to give European neonatologists a tool to perform 
their own quality assurance and a framework to facilitate the 
development of high-quaility outcome epidemiological research and 
randomised clinical trials. 
Spain Not 
available 
19 European Network for Hyperkinetic Disorders (41) EUNETHYDIS 
Network of scientists, clinicians, clinical researchers, cardiologists, 
pharmacologists and neuroscientists dedicated to the study and 
treatment of children with Attention Deficit Hyperactivity Disorder 
(ADHD) or Hyperkinesis. 
Scotland 1994 
20 European Network of Paediatric Research at the Euroepan Medicines Agency (19) Enpr-EMA 
The objectives of the network are: to increase collaboration between 
the existing networks, to build competences to be shared among the 
networks, to avoid unnecessary studies, to stimulate high quality 
research, to strengthen the European Research Area to facilitate 
recruitment and clinical trials' implementation. 
UK 2008 
21 European Organisation for Research and Treatment of Cancer (24) EORTC 
The aims of the network  are to develop, conduct, coordinate 
translational and clinical research in Europe to improve the treatments 
of cancer.  
Belgium 1962 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.3).  
Line Name Acronym Brief description Country Year 
22 European Paediatric Oncology Off-patent Medicines Consortium (42) EPOC Network that perfoms paediatric oncology pharmacology clinical trials. UK 2009 
23 European Paediatric Soft Tissue Sarcoma Study Group (43) EpSSG 
The aim of the network is to promote and manage clinical trials, 
encourage and facilitate clinical and basic science research, foster 
optimal standards of care, organise educational meetings for its 
members and other professionals, and advocate for patients with Soft 
Tissue Sarcoma. 
Italy Not 
available 
24 European Society of Anaesthesiology Clinical Trial Network (44) ESA CTN 
The aim of the network is to provide an infrastructure for clinical 
research in the fields of Anaesthesia Pain, Intensive Care and 
Emergency Medicine by transnational European collaborative studies. 
Belgium 2010 
25 European Stroke Network (45) ESN 
The aims of the network is to bring together researchers, government, 
industry and patients group associations to decrease physical, social 
and economic consequences of strokes on society by developping 
basic and clinical research. The network has the ESN Clinical Trial 
Platform that is composed of stroke centres and that also supports 
the design of Phase I and II studies and deals with the ethical and 
regulatory issues. 
Germany 2008 
26 European Stroke Research Network for Hypothermia (46) EuroHYP 
The network aims to develop, support and promote medical research 
and dissemination activities related to stroke and brain diseases in 
general, especially considering the experimental and clinical research 
related to hypothermia and its therapeutic aiming to protect the 
human health. 
Belgium 2008 
27 European Thoracic Oncology Platform (47) ETOP 
The aim of the network is to promote and to improve collaboration in 
clinical and translational research in lung cancer and mesothelioma in 
Europe. 
Switzerland 2009 
28 European Network for Intracerebral Haemorrhage (48) EURONICH 
The aim of the network is to set research priorities and conduct 
clinical trials dedicated to intracerebral haemorrhage. Germany 
Not 
available 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.4).  
Line Name Acronym Brief description Country Year 
29 European Network for the Study of Adrenal Tumours (49) ENSAT 
The network aims to improve the understanding of the genetics, 
tumourigenesis and hypersecretion in patients with adrenal tumours 
and associated familial syndromes. 
Not available 2002 
30 European Vision Institute Clinical Research (50) EVICR.net 
The aim of the network is to guarantee a high level of quality and 
excellence in ophthalmology clinical research collaborative work 
performed by the members. 
Portugal 2010 
31 European Working Group on Myelodysplastic Syndromes (51) EWOG-MDS 
The network aims to bring together clinicians and researchers with an 
interest in childhood myelodysplastic syndromes (MDS) and juvenile 
myelomonocytic leukemia (JMML), initiate collaborative studies, 
disseminate information about childhood MDS and serve as a 
resource for those being interested in childhood MDS. 
Germany 1993 
32 Family Paediatricians Medicines for Children Research Network (1, 52) FIMP-MCRN  
The network aims to develop competence, infrastructure, networking 
and training for paediatric clinical trials. This network is composed by 
20 Local Research Netwoks and 6 Sub- speciality Networks 
(vaccines, nutrition, phytotherapy, allergology, dermatology and 
gastroenterology). 
Italy 2003 
33 Finnish Investigators Network of Paediatric Medicines (18) FINPEDMED 
The network aims to improve both academic and commercial 
paediatric clinical trials  for the benefit of children's health. The 
network facilitates reliable expert services related to designing and 
conducting paediatric clinical trials. 
Finland 2007 
34 French Clinical Research Infrastructure Network (53) FCRIN 
The network aims to support investigators and sponsors to increase 
attractiveness and efficiency by gathering clinical trial units. 
The network provides information on existing structures and 
regulatory framework; consultancy on protocol, study design and 
services needed for the the conduct of clinical trials such as 
methodology, training, monitoring, pharmacovigilance, quality 
assurance, etc.  
France 2010 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.5).  
Line Name Acronym Brief description Country Year 
35 Futurenest Paediatric Network (54) Futurenest 
The network aims to ensure that clinical trials with children are 
conducted in an efficient way to increase the access of the population 
to innovative medicines. This network facilitates the recruitment of 
experts and investigators to the clinical trials.  
Hungary 2008 
36 German Hodgkin Study Group (55) GHSG The aim of the network is to optimize and standardize diagnostics, therapy and follow-up care in Hodgkin lymphoma patients. Germany 1978 
37 German Neonatal Network (56) GNN 
The network is focussed on the long-term effects of genetic, clinical 
and social risks factors, the influence of center specific treatment 
strategies and in the support of randomized clinical trials in Very Low 
Birth Weight infants. 
Germany 2008 
38 Global Allergy and Asthma European Network (57, 58) GA
2LEN 
The network aims to bring together research and clinical units to 
overcome the fragmentation in Europe in terms of allergy and asthma 
research where the diseases' prevalence continues to grow. The 
services available are a web platform for data transfer and storage, 
knowledge in biobanking, platform for clinical trials, administrative 
support and collaboration among partners. 
Germany 2005 
39 Grupo Espanol de Cancer de Pulmón (59) GECP The aim of the network is to develop the treatment of lung cancer by 
clinic research and prevention. Spain 1991 
40 Hungarian European Clinical Research Infrastructure Network (60) HECRIN 
The network aims to develop clinical research by providing 
infrastructures. Hungary 2006 
41 Haemato Oncology Foundation for Adults in the Netherlands (61) HOVON 
The aim of the network is to improve and promote treatment methods 
for adult patients with malignant haematological disorders, such as 
leukaemia and lymphoma. 
Netherlands 1985 
42 Histiocyte Society (62) HS 
The aim of the network is to advance knowledge about and improve 
outcomes for patients with histiocytic disorders through clinical and 
basic research and education. 
USA 1985 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.6). 
Line Name Acronym Brief description Country Year 
43 Innovative Therapies for Children with Cancer (63) ITCC 
The aim of the network is to  develop novel therapies for the 
treatment of paediatric and adolescent cancers in cooperation with 
regulatory bodies, pharmaceutical companies, parents and patients. 
The expertise of the network is in conducting early phase trials. 
France 2003 
44 International Breast Cancer Study Group (64) IBCSG 
The aim of the network is to develop innovative clinical cancer 
research to improve the outcome of women with brest cancer.  Switzerland 1977 
45 International Berlin/ Frankfurt/ Munsten (BFM) Study Group (16) I-BFM-SG 
The aim of the network is to promote both research and clinical care 
for children and adolescents with leukemia and lymphoma, making 
use of the large population of patients.   
Germany 1987 
46 International Extranodal Lymphoma Study Group (65) IELSG 
The aim of the network is to bring together scientists from different 
institutions to study specific extranodal sites of involvement by a 
lymphoma. 
Switzerland 1998 
47 
International Neurotrauma Research 
Organization  
Internationale Gesellschaft zur Erforschung 
von Hirntraumata (66) 
INRO / IGEH 
The aim of the network is to improve the recovery of patients who 
suffer a brain or spinal cord injury through helping hospitals to 
implement evidence-based medical care by collaborating on clinical 
research to continuously improve the scientific foundations. 
Austria Not 
available 
48 International Rare Cancers Initiative (67) IRCI 
The aim of the network is to facilitate the development of international 
clinical trials for patients with rare cancers in order to boost the 
progress of new treatments for these patients. This is an initiative 
between UK National Cancer Research Network (UK CRN), Cancer 
Research UK (CR-UK), US National Cancer Institute (US NCI) and 
the EORTC.  
UK 2011 
49 
International Society of Paediatric Oncology 
European Neuroblastoma Research 
Network (68) 
SIOPEN-R-
NET 
The network aims to co-ordinate prospective multinational risk 
adapted trials and to be the basis to exchange the experience 
acquired, to disseminate results and to inform users.  
Austria 2014 
50 International Society of Paediatric Oncology Renal Tumour Study Group (69) SIOP-RTSG 
The network aims to plan and implement new studies in children and 
adolescents affected by kidney tumours.  Germany 2007 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.7). 
Line Name Acronym Brief description Country Year 
51 Irish Clinical Research Infrastructure Network (70) ICRIN 
The network supports clinical research and investigators in assuring 
that the standards of efficiency, ethical principals and national 
regulatory requirements are complied in order to improve the quality 
of research. The network provides templates, forms, SOPs to be used 
in clinical trials. 
Ireland 2006 
52 Irish Paediatric Clinical Research Network (71) IPCRN 
It is a network of key opinion leaders in paediatric care created to 
promote high-quality basic and clinical research in children to further 
the understanding of paediatric illness and to develop safe and 
effective treatment options.  
Ireland 2009 
53 Italian Clinical Research Infrastructure Network (72)  ItaCRIN 
A network of Italian institutions of excellence in the field of clinical 
research. It is coordinated by the Istituto Superiore di Sanitá. The aim 
of the network is to support clinical trials of European projects 
involving differents ECRIN partners and Italy by giving support of 
technical and scientific nature. 
Italy 2012 
54 Medicines for Children Research Network (NL) (21) MCRN 
The aim of the network is to stimulate high quality research on drugs 
in children in the Netherlands, to ultimately improve drug therapy by 
providing expertise and to coordinate logistical support to academic 
investigators and pharmaceutical companies. 
Netherlands 2008 
55 National Health Service Research Scotland (73) NRS  
The network aims to provide the best environment to high quality 
clinical research and to give support to the patients that participate in 
clinical research. The network is organised in 5 regional nodes: North, 
East, South-East and West. The network includes 6 topic research 
networks (Cancer (SCRN that is divide in 4 hubs: West, North, South 
East and East), Medicines for Children (ScotCRN), Dementia 
(SDCRN), Diabetes (SDRN, 2006), Mental Health (SMHRN, 2009), 
Primary Care (SPCRN, 2002) and Stroke (SSRN, 2006)). 
Scotland 2010 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.8). 
Line Name Acronym Brief description Country Year 
56 National Institute for Health Research Clinical Research Network (74) NIHR-CRN 
The network aims to provide the infrastructure that allows high quality 
research and to give support to the patients that participate in clinical 
research. This network is organized in 6 topic research networks 
(Cancer, Dementia and Neurodegenerative Diseases, Diabetes, 
Medicine for Children, Mental Health and Stroke), a Primary Care 
Research Network and a Comprehensive Clinical Research Network  
that cover all other disease areas and 15 Local Research Networks. 
UK 2006 
57 National Institute for Social Care and Health Research Clinical Research Centre (75) NISCHR CRC 
The network aims to support the development and delivery of high-
quality clinical research. The network also provides training for people 
involved in clinical research, namely Good Clinical Practice, Informed 
Consent Form, Communication Skills and Core Research Skills and 
an annual meeting. This network is organized in 9 topic research 
networks (Children and Young People's (CYPRN, 2006), Dementias 
and Neurodegenerative Diseases (NEURODEM Cymru),  Diabetes 
(DRN Wales), Thematic RN for Emergency and Unscheduled Treat 
(TRUST), Wales Epilepsy (WERN, 2004), Learning Disabilities, 
Autism and Neurodevelopmental Disorders (LDAN), Mental Health 
(MHRN-C, 2006), Public Health Improvement (PHIRN, 2006) and 
Older People & Ageing & Development (OPAN Cymru) and also the 
Wales Cancer Research Network (WCRN, 1998), all networks with 
websites . The main organization of the network is the regional 
networks: North Wales, South East and South West Research 
Networks and Primary Care. 
Wales 2010 
58 Network of the Coordinating Centres for Clinical Trials (76) KKS-Network 
The network is a scientific service provider with the aim of 
implementing clinical trials among the network to ensure the 
successful implementation of clinical trials. The network also provides 
training and it has a relevant role in improving the regulatory 
framework.  
Germany Not 
available 
59 Network of Excellence for Research in Paediatric Critical Care (77) SKIC 
The network aims to create guidelines in the Intensive Care Units for 
children with scientific basis. Netherlands 2009 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.9). 
Line Name Acronym Brief description Country Year 
60 Network Neonatale Italiano (78) NNI 
The aim of the network is to improve the quality and care of newborns 
and their families by research programs, education and quality 
improvement. This network is associated to the Vermont-Oxford 
Network (VON). 
Italy 1999 
61 Newcastle Children's Cancer & Leukaemia Group (CCLG) Pharmacology (79) N-CCLG 
The network aims to promote the conduction of clinical pharmacology 
trials for children and adolescents. The coordinating Centre is the 
Northern Institute for Cancer Research at Newcastle University. 
UK 2000 
62 Northern Ireland Clinical Research Network (80) NICRN 
The aim of the network is to enable a well-resourced network of 
skilled staff which facilitates investigators and patients and delivers 
high quality clinical research studies among the Health and Social 
Care in the Northern Ireland. The network is organized in the 
following Groups: Cardiovascular, Children, Critical Care, Dementia, 
Diabetes, Mental Health, Primary Care, Renal, Respiratoty Health, 
Stroke and Vision. 
Northern 
Ireland 2008 
63 Norwegian Clinical Research Network (81) NORCRIN 
The aim of the network is to strengthen and facilitate collaboration on 
clinical research in Norway and to integrate clinical research in 
Europe by providing research support to clinical trials.  
Norway Not 
available 
64 Paediatric European Digestive Diseases Clinical Research Network (82) PEDDCReN 
The aim of the network is to study effective medicines for paediatric 
patients in the speciality of gastroenterology, hepatology and nutrition. 
The network also aims to play a role in influencing the development of 
study plans and protocols. 
UK 2013 
65 
Paediatric European Network for the  
treatment of AIDS and infectious diseases 
(83) 
PENTA-ID 
Collaboration between paediatric HIV centres to address questions 
about treatment for children with HIV that are not answered, 
performing clinical trials, cohort syudies and training. Close 
collaboration with adult trial networks.  
Italy 2004 
66 Paediatric Network of Clinical Investigators Centre (15) CICPed 
The aim of the network is to  create interactions between the 
researchers, the paediatricians and the pharmaceutical industry to 
conduct paediatric clinical research projects in France. 
France 2000 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.10). 
Line Name Acronym Brief description Country Year 
67 Pediatric Infectious Disease Group of Switzerland (84)  PIGS 
The aims of the network are to set standards of care for pediatirc 
patients with infectious diseases and to develop protocols for studies 
in the area of pediatric infectious disease. 
Switzerland 2001 
68 Pedriatic Rheumatology International Trials Organisation (17) PRINTO 
The aim of the network is perform to clinical trials for paediatric with 
and without the support of pharmaceutical industry. Italy 1996 
69 Platform for European Preparedness Against (Re-)emerging Epidemics (85) PREPARE 
The network aims to conduct observational studies and randomised 
clinical trials in children and in adults. The network will develop pre-
emptive solutions to ethical, administrative, regulatory and logistical 
bottlenecks that prevent a rapid response in the face of new threats. 
Belgium 2014 
70 Prevéncion com Dieta Mediterránea (86) PREDIMED 
The network was created to perform a clinical trial to assess the 
influence that the Mediterranean Diet may have in people with high 
cardiovascular risk. The network also aims to develop an 
epidemiologic nutricional study and other sub-studies (interventional 
and observational). 
Spain 2002 
71 Polish Clinical Research Infrastructures Network (23) POLCRIN 
The network aims to integrate and strengthen medical science in 
Poland. Poland 2007 
72 Portuguese Clinical Research Infrastructure Network (87) PtCRIN 
The network aims to facilitate and improve quality in clinical research 
and to increase research collaboration for the benefit of the patients 
by developing clinical research infrastructures.  
Portugal 2012 
73 Red Espanola de Esclerosis Múltiple (88) REEM 
The aim of the network is to study the causes and treatment of 
multiple sclerosis by the collaboration between national 
investigational groups. 
Spain 2007 
74 Red de Investigación Cardiovascular (89) RIC 
The aim of the network is to reduce the impact of the cardiovascular 
diseases on the survival and quality of life by promoting translational 
research. This network resulted from the union of 3 former networks: 
RECAVA, REDINSCOR and HERACLES. 
Spain 2012 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.11). 
Line Name Acronym Brief description Country Year 
75 Red de Investigación Cooperativa en Enfermedades Tropicales (90) RICET 
The aim of the network is to study the tropical diseases that are 
becoming to be present in Europe due to the international mobility.  Spain 2002 
76 Red de Investigación en Salud Materno-Infantil y del Desarrollo (91) Red SAMID 
The aim of the network is to generate high quality scientific 
knowledge in the area of neonatology to improve the quality of health 
care. The main lines of work is to assess the potential impact of 
certain perinatal processes on children's growth and development. 
One of the RETIC Network (Redes Temáticas de Investigación 
Cooperativa en Salud) of Spain that promotes the collaboration 
between institutions of the National Health System. 
Spain 2008 
77 Red Temática de Investigación Cooperativa de Centros de Cáncer (92) RTICCC 
The aim of the network is to stimulate the research in cancer diseases 
and to consolidate the infrastructures of collaboration between 
institutions of the National Health System. 
Spain 2003 
78 Réseau d'Investigations Pédiatriques des Produits de Santé (93) RIPPS 
The aim of the network is to facilitate the conduct of clinical trials with 
children in France and to ensure the quality of the medicinal products.  
This network is organized by sub-networks: RIPPS DéfiScience 
(multidisciplinary), PERENE Epilepsy, RMNMI  (pediatric 
neuromusculaires diseases) and Pediatric Emmergency Network). 
France 
2005 
(PERENE, 
2011), 
(RMNMI, 
2010) 
79 Romanian Clinical Research Infrastructure Network (23) ROCRIN The aim of the network is to develop clinical research. Romania 
Not 
available 
80 
Study Group of Medical Tumor Therapy - 
Arbeitsgemeinschaft medikamentose 
Tumortherapie (94) 
AGMT 
The aim of the network is to carry out clinical trials to improve the 
results of patients suffering from malignant tumours and to perform 
translational research. 
Austria 2007 
81 Swedish Clinical Research Infrastructure Network (95) SweCRIN 
The aim of the network is to improve the quality and the efficacy of 
clinical research in Sweden by facilitating the collaboration between 
clinical trial units and also with international clinical research. The 
network intends to stimulate the dialogue with the regulatory 
authorities, associations and networks.   
Sweden 2003 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.12). 
Line Name Acronym Brief description Country Year 
82 Swiss Clinical Trial Organisation (96) SCTO 
The network aims to position swiss clinical research in the 
international competition with respect to innovation and quality. The 
network provides quality assurance, data management, education 
and training, coordination of clinical trials, information for the public, 
funding opportunites and meetings.  
Switzerland Not 
available 
83 Swiss Group for Clinical Cancer Research (97) SAKK 
The aim of the network is to investigate new cancer therapies and to 
improve the existing tumor treatments in order to cure the disease, 
prolong survival and improve life quality of patients. The network is 
organised by project groups: breast cancer, lung cancer, leukemia, 
lymphoma, gastrointestinal cancer, new anticancer drugs and 
urogenital tumors. The network has 2 sections of pathology and radio-
oncology; 2 networks: for cancer predisposition testing and 
counseling (CPTC) and for outcomes research; and 4 working groups 
(central nervous system tumors, head and neck cancer, melanoma 
and control and palliative cancer care. 
Switzerland Not 
available 
84 
 
 
 
Swiss Group for Clinical Cancer Research 
(98) SPOG 
The aim of the network is to promote patient-oriented cancer research 
in the field of paediatric oncology through cooperative, 
predominantely international studies. This network has the Swiss 
Childhood Cancer Registry and the SPOG's Tumor Bank. 
Switzerland Not 
available 
85 Swiss Research Network of Clinical Paediatric (99)   SwissPedNet 
The aim of the network is to promote, facilitate, coordinate and 
conduct clinical trials devoted to children ranging from newborns to 
adoloscents in all paediatric diseases. The ultimate goal is to enhance 
clinical research in pediatrics both by supporting pediatric clinician 
scientists to foster their commitment to high-quality clinical research 
and by encouraging an overall increased acceptance in the 
community of trials in children. 
Switzerland 2012 
86 The Trauma Audit & Research Network (100) TARN 
The aim of the network is to perform research with highly skilled 
teams to provide relevant information to help health professionals and 
managers to improve their services. 
UK Not 
available 
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Table 2 – List of the European Clinical Networks: name, acronym, brief description, country and year of establishment (cont.13). 
Line Name Acronym Brief description Country Year 
87 United Kingdom Clinical Research Network (101)  UKCRN 
The aim of the network is to ensure that the clinical research networks 
across the UK work together in an integrated manner to share 
experiences, develop joint initiatives and promote partnership 
between networks. The network is formed by the national networks of 
UK: National Institute for Health Research (NIHR CRN), Northern 
Ireland Clinical Research Network (NICRN), National Health Service 
Research Scotland (NRS) and National Institute for Social Care and 
Health Research Clinical Research Centre (NISCHR CRC).  
UK Not 
available 
88 United Kingdom Paediatric Vaccine Group (20) UKPVG 
The aim of the network is to improve education, training and high 
quality research through collaboration among the participating 
centres. 
UK 2001 
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Table 3 (See Appendix 1) lists other parameters that help to characterise the 
networks: national/international networks, number of members, public/private 
networks, target disease, relevant activities (e.g., studies, publications) and 
website address. 
 
According to the collected data, 51 of the networks are national, i.e., 58% of the 
networks perform their activities among members inside of the country of the 
network. The other 42% of the networks are international.  
 
The number of members varies from network to network. 14 of the networks have 
10 or less members; 27 networks have between 11 and 50 members and 13 
networks have between 51 and 100 members. 11 networks have more than 100 
members and the number of members varies from 100 to 6200. Finally, 6 
networks have as members all the hospitals of the corresponding country and in 
this case it was not possible to quantify. There are other 17 networks that it was 
not possible to quantify neither qualify the number of members. 
 
Considering the identified networks, 61% (54 networks) of them are private 
organisations, whereas 38% (33 networks) are public organisations and 1% (1 
network) is a public/private organisation. 
 
Further, 64% (56 networks) of the networks are thematic, whereas 36% (32 
networks) are general. Among the 32 general networks, 30% (10 networks) are 
focused in paediatric diseases. Among the 55 thematic networks, 31% (17 
networks) are focused in paediatric diseases. 
The thematic networks are related to diseases such as: radiotherapy, 
AntiPhospholipid Syndrome, disease and long-term development of preterm 
infants, allergology and asthma, ophthalmology, intracerebral haemorrhage, 
anaesthesiology, stroke, traumatic brain injury, cystic fibrosis, blood and marrow, 
neonatal diseases, attention deficit hyperactivity disorder (ADHD) and 
hyperkinesis,  histiocytic disorders, intensive care, gastroenterology, hepatology, 
nutrition, HIV and other infectious diseases, infectious diseases, rheumatic 
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diseases, infectious diseases outbreak, multiple sclerosis, heart diseases, tropical 
diseases, trauma, vaccines, oncology and specific areas of oncology like brest 
cancer, liver tumor, chronic lymphocytic leukemia, soft tissue sarcoma, lung 
cancer and mesothelioma, adrenal tumors, myelodysplastic syndromes (MDS) in 
childhood and juvenile myelomonocytic leukemia (JMML), Hodgkin lymphoma and 
malignant haematological disorders.  
Among the thematic networks (55 networks), 45% of the networks are cancer 
related. 
 
Relevant activities of the networks were also collected from the corresponding 
websites. Therefore, networks may have other activities that as are not referred in 
the website are not mentioned here. Relevant activities were defined as all 
activities that contribute to clinical research such as: clinical trials, observational 
studies, projects, meetings, trainings and publications. 
 
3.2. Discussion 
 
Almost all European countries have networks. The UK is the country with the 
highest number of CRN, 11 networks, followed by Germany with 10 networks, 
Spain and Switzerland with 8 networks, Belgium and Italy with 7 networks and 
Austria, France, and the Netherlands with 5 networks. Hungary, Ireland, Poland, 
Portugal, Scotland and the USA have 2 networks. Finally, Czech Republic, 
Denmark, Finland, Ireland, Luxemburg, Northern Ireland, Norway, Romania, 
Sweden and Wales have 1 network. Therefore, it can be concluded that the richest 
countries have a higher number of networks. This fact was already expected as 
wealthy countries have a stronger clinical research tradition, better clinical 
research policies and greater budget to dedicate to this type of organisations and 
research. 
 
The identified networks were established between 1962 and 2014. Figure 1 
presents the number of established networks per decade in Europe. The 2000s 
was the decade of the “baby boom” of networks in Europe with 42 new networks. 
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Apparently, the odds are that the current decade will also have a great number of 
new networks. This tendency comes in line with the new paradigm in Drug 
Development where stakeholders have been progressively concluding that the 
success of innovative drugs and therapies will not happen in an isolated lab of the 
academy, or in the lab of a pharmaceutical company or in the bed of a University 
Hospital. Collaboration and partnership are essential in Drug Development and 
Clinical Research.  
 
 
Figure 1 - Number of established networks per decade 
 
Table 3 (See Appendix 1) lists other parameters that help to characterise the 
networks: national/international networks, number of members, public/private 
networks, target disease, relevant activities (e.g., studies, publications) and 
website address. 
 
According to the collected data, 51 of the networks are national, i.e., 58% of the 
networks perform their activities among members inside of the country of the 
network. The other 42% of the networks are international. Therefore, there is a 
balance between the number of international and national networks. Nevertheless, 
if analysed along time, the conclusion is not the same (See Figure 2). Until the 
2000s, there is a predominance of the international networks, whereas in the 
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2000s there is a predominance of the national networks and in the 2010s it seems 
that there is a balance between the number of international and national networks. 
The predominance of the national networks in the 2000s is related to the creation 
of the national clinical research infrastructure networks.  
 
 
Figure 2 - % of International versus National networks per decade 
 
The number of members varies from network to network. As represented in the 
graph of Figure 3, 14 networks have 10 or less members; 27 networks have 
between 11 and 50 members and 13 networks have between 51 and 100 
members. 11 networks have more than 100 members where the number of 
members varies from 100 to 6200. Finally, 6 networks have as members all the 
hospitals of the corresponding country and in this case it was not possible to 
quantify. There are other 17 networks that it was not possible to quantify neither 
qualify the number of members. The most common number of members is 
between 11 and 50 members. Therefore, the number of member between 11 and 
55 seems to be the optimal number to the well work of a network. 
 
0%
25%
50%
75%
100%
%
  
Year
% of International vs National networks per decade 
International
National
 58 
 
 
 Figure 3 – Networks grouped by number of members. 
 
61% (54 networks) of the networks are private organisations, whereas 38% (33 
networks) are public organisations and 1% (1 network) is a public/private 
organisation (Figure 4). Although the majority of the networks are private, 
significant part of the budget of these networks are paid by public funding from the 
country national budget and from the European Commission. 
 
Figure 4 – Private, public and public/private networks.  
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philosophy of the networks is the share of a common interest, in this case a 
disease or an area of medicine.  
Among the 32 general networks, 30% (10 networks) are focused in paediatric 
diseases. Among the 55 thematic networks, 31% (17 networks) are focused in 
paediatric diseases (Figures 5.1, 5.2 and 5.3). It can be concluded that the interest 
by paediatric disease is the same among the thematic and the general networks. 
 
 
Figure 5.1 - Thematic networks versus general networks. 
 
 
Figure 5.2 - Thematic networks: all diseases versus paediatric diseases. 
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Figure 5.3 - General networks: all diseases versus paediatric diseases. 
 
The thematic networks are related to diseases such as: radiotherapy, 
AntiPhospholipid Syndrome, disease and long-term development of preterm 
infants, allergology and asthma, ophthalmology, intracerebral haemorrhage, 
anaesthesiology, stroke, traumatic brain injury, cystic fibrosis, blood and marrow, 
neonatal diseases, attention deficit hyperactivity disorder (ADHD) and 
hyperkinesis,  histiocytic disorders, intensive care, gastroenterology, hepatology, 
nutrition, HIV and other infectious diseases, infectious diseases, rheumatic 
diseases, infectious diseases outbreak, multiple sclerosis, heart diseases, tropical 
diseases, trauma, vaccines, oncology and specific areas of oncology like brest 
cancer, liver tumor, chronic lymphocytic leukemia, soft tissue sarcoma, lung 
cancer and mesothelioma, adrenal tumors, myelodysplastic syndromes (MDS) in 
childhood and juvenile myelomonocytic leukemia (JMML), Hodgkin lymphoma and 
malignant haematological disorders.  
Among the thematic networks (55 networks), 45% are cancer related networks.  
It can be concluded that among the clinical research environment, there is a 
special focus in the cancer diseases and in paediatric diseases. This is probably 
due to the high number of unmet medical needs in oncology and in paediatric 
populations. 
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Relevant activities of the networks were also collected from the corresponding 
websites. Therefore, networks may have other activities that as are not referred in 
the website are not mentioned here. Relevant activities were defined as all 
activities that contribute to clinical research such as: clinical trials, observational 
studies, projects, meetings, trainings and publications. Analysing the relevant 
activities of the clinical research networks, there are significant evidences that 
clinical research networks have a positive impact in clinical research and are 
considered a valid stakeholder in clinical research environment. It is also a fact 
that this impact could be optimized.  
 
In order to maximise the contribution of clinical research networks to the 
development of new drugs and therapies, it is essential to increase and improve 
the communication among stakeholders. 
It would be useful to create an on-line database of clinical research networks, 
allowing the use of tools such as search engines that could be located in a 
dynamic website. The website could be fed with updated news about the clinical 
research networks, such as an updated list of the clinical research networks and 
contacts, active clinical trials, meetings, trainings and main achievements and 
could also have a forum for scientific discussion for all stakeholders (industry, 
academy, researchers, investigators, patients and authorities). 
It could also be helpful to the clinical research networks to have access to a set of 
basic rules/tips to help in the management and communication of the networks. 
For example, regular newsletters help to keep the members informed and 
motivated to participate in the network activities. 
Other good tip is to keep a public updated portfolio of the projects. Portfolios are 
very useful as they characterise the network activities, avoid the duplication of 
projects already done and also work as a brainstorm for new projects. 
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4. Conclusion 
 
This report was written as part of the Master’s degree in Pharmaceutical Medicine 
and it presents the information about the search of the existing European clinical 
research networks that performed between December 2013 and May 2014.  
 
The data collected from each clinical research network was: name, acronym, brief 
description, country, year of establishment, national/international networks, 
number of members, public/private networks, target disease, relevant activities 
(e.g., studies, publications) and website address. 
 
Eighty-eight clinical research networks were identified in the Internet between 
december 2013 and may 2014. It was a great challenge to identify the networks, 
as information about networks can only be obtained in the websites of each 
network. Further, most of the websites do not provide much information and part of 
the websites were not updated.  
 
Networks should give special attention to the design and contents of the websites, 
as websites are the interface/ image of the organisation. In order to better 
characterise this landscape of research networks and complete the information in 
this thesis, more information should be obtained to achieve better quality. By the 
use of a well developed questionnaire administered to the networks will allow to 
gather complete and accurate information, especially regarding the relevant 
activities. 
 
Clinical research networks were identified in almost all European countries and  
the wealthiest countries have the higher number of networks.   
 
The year of establishment of the networks vary between 1962 and 2014. The 
2000s was the decade of the “baby boom” of networks in Europe with 42 new 
networks. It is expected that the current decade will also have a great number of 
new networks. This confirms that stakeholders believe that the success of 
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innovative drugs and therapies depends of the collaboration between academy 
and pharmaceutical companies.    
 
It was verified that the majority of the networks are thematic and that there is a 
special focus in cancer diseases and in paediatric diseases. It seems that clinical 
research networks are being created due to the number of unmet medical needs in 
oncology and in paediatric diseases. 
 
Analysing the relevant activities of the clinical research networks, there is evidence 
that clinical research networks have a positive impact in clinical research and are 
considered a valid stakeholder in the clinical research environment. It is also a fact 
that this impact could be optimized. It would be useful to create a search engine 
with an on-line database of the clinical research networks. Further, this search 
engine could be located in a dynamic website. The website could be fed with 
updated news about the clinical research networks, such as active clinical trials, 
scientific meetings and main achievements. Finally, it could also have a forum for 
scientific discussion for all stakeholders (industry, academy, researchers, 
investigators, patients and authorities). 
 
Following this first step of collection of the European clinical research networks, 
conclusions should be analysed and released in a publication. The next step is to 
analyse the American clinical research networks.  
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address. 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
1 ACORRN Nat Not 
available private radiotherapy 
In the first 4 years this network achieved: 7 grant applications, 8 
peer reviewed publications, 1 Lancet Oncology editorial, 1 audit 
of the Royal College of Radiologists guidelines, 2 working party 
reports, research radiographer starter pack, £41 million strategy 
document and business plan and Image Guided Radiotherapy 
Road Map. 
http://www.actionradiotherapy.org/ 
 
2 APS ACTION Inter 31 
public/ 
private 
AntiPhospholipi
d Syndrome Not available. http://www.apsaction.org 
3 ATCRIN Nat Not 
available public all diseases Not available. http://atcrin.at 
4 BPDN Nat 7 private paediatric diseases One survey ongoing. http://www.pediatrie.be/pediatricdrug.htm 
5 BIG Inter 49 private breast cancer 
24 ongoing clinical trials and 8 closed clinical trials. 3 ongoing 
projects (INTEGRATE, EURECA and BIOMATERIAL 
INVENTORY).  
http://www.bigagainstbreastcancer.org 
6 CESAR Inter Not 
available private oncology 
This network provides education, training and several meetings 
per year and the CESAR award. 23 publications between 2002 
and 2012, 20 abstracts and 7 ongoing clinical trials and 29 closed 
clinical trials. 
http://www.cesar.or.at 
7 CRP-Santé Nat 48 public all diseases 154 research projects and publication of 107 peer-reviewed papers until 2012, 14 ongoing projects. https://www.crp-sante.lu 
8 SIOPEL Inter 100 private childhood liver tumor 
7 ongoing projects, 7 closed clinical trials, 64 publications 
between 1993 and 2014. http://www.siopel.org/ 
9 CZECRIN Nat Not 
available public all diseases Not available. This network does not have website. 
10 CIRM Nat 10 private all diseases 2 ongoing multicenter clinical trials funded by 7th Framework Programme and 7 Italian projects.  http://www.cirm.net 
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 1). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
11 DCRIN Nat Not 
available public all diseases 8 ongoing clinical trials. http://ctu.dk 
12 DCLLSG Nat Not 
available private 
chronic 
lymphocytic 
leukemia 
2 ongoing clinical trials, 33 closed clinical trials and 75 
publications between 1996 and 2014. http://www.dcllsg.de 
13 NFU Nat 8 public all diseases 
Clinical researchers from the network are obliged to attend the 
Basic Regulation and Organisation for Clinical Research (CHUNK 
course). The network has also a PhD program, where 
researchers are trained to become independent. 
http://www.nfu.nl 
14 EBIC Inter Not 
available private 
traumatic brain 
injury 
The network provides different meetings per year.  
5 closed studies and 5 ongoing studies, 59 publications between 
1997 and 2011. 
http://www.ebic.nl 
15 ECRIN Inter 
22 
national 
hubs + 12 
institutions 
private all diseases The network provides information, consultancy and services for 
non-profit academic clinical trials. www.ecrin.org 
16 ECFS-CTN Inter 30 private cystic fibrosis  
23 ongoing studies and 7 new studies have been reviewed to be 
started in 2014, 7 publications and Annual training day on Clinical 
Reseach and annual conference. 
https://www.ecfs.eu/ctn 
17 EBMT Inter Not 
available private 
blood and 
marrow  
15 non-interventional prospective sudies, 30 retrospective 
studies, 7 prospective clinical trials, more than 560 publications in 
peer-reviewed scientific journals. 
https://www.ebmt.org/Contents/Pages/Default.aspx 
18 EuroNeoNet Inter Not 
available private 
neonatal 
diseases 
The network has an up-to-date technological neonatal platform 
based on the Internet. A follow-up minimal dataset for long-term 
outcomes evaluated at 48 months is being developed. 
http://www.euroneonet.eu 
 
 
 
 72 
 
Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 2). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
19 EUNETHYDIS Inter 160 private 
attention deficit 
hyperactivity 
disorder 
(ADHD) or 
hyperkinesis 
The networks has held an annual for the last 20 years, and it has 
a "Guideline Group" that has published 5 papers.  http://adhd-adduce.org/page/view/35/EUNETHYDIS 
20 Enpr-EMA Inter 18 public paediatric diseases 
Annual workshop since 2008, creation EnprEMA Network 
Database, avaliation of the members of the network. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages
/partners_and_networks/general/general_content_00
0303.jsp&mid=WC0b01ac05801df74a 
21 EORTC Inter 300 hospitals private oncology 
Every year about 6000 new patients are enrolled in the EORTC 
clinical trials; 30 protocols are in the recruitment period and over 
50000 patients are in the follow-up. EORTC has more than 
180000 patients. EORTC has an official journal and every they 
organise courses and meetings. 
http://www.eortc.org/ 
22 EPOC Inter Not 
available private 
paediatric 
oncology Not available. http://research.ncl.ac.uk/epoc/ 
23 EpSSG Inter 163 private paediatric soft tissue sarcoma 3 clinical trials in the recrutiment period.  http://www.epssgassociation.it/ 
24 ESA CTN Inter 6200 private Anaesthesiology 3 ongoing clinical trials and 6 closed clinical trials. http://www.esahq.org/research/clinical-trial-network 
25 ESN Inter 29 private Stroke 96 publications between 2009 and 2012.  http://www.europeanstrokenetwork.eu 
26 EuroHYP Inter 25 private Stroke Annual Meeting, 8  ongoing clinical trials, 7 publications. http://www.eurohyp.org 
27 ETOP Inter 51 private lung cancer 
mesothelioma 5 projects that include ongoing clinical trials. http://www.etop-eu.org 
28 EURONICH Inter 14 
countries private 
intracerebral 
haemorrhage 3 ongoing clinical trials. http://www.euronich.de (Not working) 
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 3). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
29 ENSAT Inter Not 
available private adrenal tumors 4 ongoing clinical trials and 9 publications. http://www.ensat.org 
30 EVICR.net Inter 86 private Ophthalmology The network provides annual meeting, certification of the clinical 
sites. 11 ongoing clinical trials. http://www.evicr.net 
31 EWOG-MDS Inter 11 private 
myelodysplastic 
syndromes 
(MDS) in 
childhood and 
juvenile 
myelomonocyti
c leukemia 
(JMML) 
5 ongoing studies and 32 publications between 1997 and 2012. http://www.ewog-mds.org/ 
32 FIMP-MCRN Nat 
6000 
paediatrici
ans 
private paediatric diseases 
Training programe with training courses for the researchers, 3 
epidemiological post-marketing studies. 
This network does not have website. 
 
33 FINPEDMED Nat 95 private 
paediatric 
diseases Not available. 
http://www.finpedmed.com/index.php?page=141&lan
g=2 
34 FCRIN Nat Not 
available public all diseases Not available. http://www.fcrin.org/en 
35 Futurenest Nat 5 private paediatric diseases Not available. http://www.futurenest.hu/ 
36 GHSG Nat 400 governa
nmental 
Hodgkin 
lymphoma 
The network provides an international symposium every 3 years, 
4 ongoing clinical trials and 18 closed clinical trials. http://en.ghsg.org 
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 4). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
37 GNN Nat 38 public 
disease and 
long-term 
development of 
preterm infants 
1 multicenter study completed and 1  ongoing study. http://www.vlbw.info/index-e.html 
38 GA2LEN Inter 87 private allergology and 
asthma 4  ongoing projects. http://www.ga2len.net/ 
39 GECP Nat 132 private lung cancer 7 ongoing clinical trials and 60 closed clinical trials.  http://www.gecp.org 
40 HECRIN Nat 143 public all diseases Not available. http://www.ett.hu/hecrin/hecrin.htm 
41 HOVON Inter 
80% of 
the 
hospitals 
of 
Beligium 
and 
Netherlan
ds 
private 
malignant 
haematological 
disorders 
6 planned clinical trials, 21 ongoing clinical trials and 56 closed 
clinical trials. http://www.hovon.nl  
42 HS Inter 220 private histiocytic disorders  1 ongoing clinica trial, 3 closed studies, 33 publications. http://www.histiocytesociety.org/ 
43 ITCC Inter 52 private 
paediatric 
cancer 
diseases 
13  ongoing clinical trials, training and education of the healthcare 
professionals in clinical research; clarification of parents about 
clinical research. 
http://www.itcc-consortium.org/itcc-clinical-trial-
committee.php 
44 IBCSG Inter 88 private breast cancer 
3 ongoing clinical trials and 38 closed clinical trials. 301 
publications between 1982 and 2014. The network also has the 
IBCSG Tissue Bank and the Central Pathology Office. 
http://www.ibcsg.org 
45 I-BFM-SG Inter 32 private 
paediatric 
leukimia and 
lymphoma 
15 closed multicenter studies and ongoing 20 studies. http://www.bfm-international.org/index.php 
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 5). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
46 IELSG Inter 54 private extranodal lymphoma 
9  ongoing clinical trials, 49 publications between 1999 and 2014, 
33 oral presentations between 1999 and 2013 and 42 posters 
between 1998 and 2013. 
http://www.ielsg.org 
47 INRO / IGEH Inter 
Not 
available private brain injury 
2 ongoing projects, 8 closed projects, 28 publications between 
2000 and 2014. http://www.igeh.org 
48 IRCI Inter 4 private rare cancers 11 ongoing clinicaltrials, 2 meetings per year. http://www.irci.info 
49 SIOPEN-R-NET Inter 21 private neuroblastoma Network under construction. https://www.siopen-r-net.org/ 
50 SIOP-RTSG Inter 10 private paediatric kidney tumors 
1 ongoing clinical trial, 6 closed clinical trials, 154 publications 
between 2003 and 2014. http://web.visu.uni-saarland.de/rtsg/ 
51 ICRIN Nat 7 public all diseases The network provides courses and workshops. http://www.molecularmedicineireland.ie/icrin 
52 IPCRN Nat 
64 
members 
from more 
than 23 
hospitals 
public paediatric diseases 10 ongoing clinical trials, 39 funded research projects.  
http://www.nationalchildrensresearchcentre.ie/resear
c/ipcrn 
53 ItaCRIN Nat Not 
available public all diseases Not available. 
http://www.itacrin.it/ecrin/mod/resource/view.php?id=
48 
54 MCRN Nat 
8 
Regional 
Research 
Clusters  
public paediatric diseases Not available. http://www.mcrn.nl 
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 6). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
55 NRS Nat 
all public 
hospitals 
in 
Scotland 
public all diseases 
Studies of the Scottish network are registered on the UK Clinical 
Research Network Portfolio Database. 
The UK Clinical Research Network Portfolio Database has 14251 
studies (closed and ongoing) since 2006.  
http://www.nhsresearchscotland.org.uk/ 
http://www.scrn.org.uk 
http://www.scotcrn.org/ 
http://www.sdcrn.org.uk 
http://www.sdrn.org.uk 
http://www.smhrn.org.uk 
http://www.sspc.ac.uk/ 
http://www.ssrn.org.uk 
56 NIHR-CRN Nat 
all public 
hospitals  
in England 
public all diseases 
Studies of the English network are registered on the UK Clinical 
Research Network Portfolio Database. 
The UK Clinical Research Network Portfolio Database has 14251 
studies (closed and ongoing) since 2006.  
http://www.crncc.nihr.ac.uk 
57 NISCHR CRC Nat 
24 
hospitals 
sites 
public all diseases 
The studies on the NISCHR Clinical Research Portfolio has 953 
studies (in set-up, open and closed) since 2008. 
Studies of the Welsh network are also registered on the UK 
Clinical Research Network Portfolio Database. 
The UK Clinical Research Network Portfolio Database has 14251 
studies (closed and ongoing) since 2006. 
117 articles between 2008 and 2013. 
http://www.wales.nhs.uk/sites3/home.cfm?orgid=580 
http://www.wales.nhs.uk/sites3/home.cfm?orgid=970 
http://www.neurodemcymru.org/ 
http://diabeteswales.org.uk 
http://www.trustresearch.org.uk/en 
http://www.wern.swan.ac.uk 
http://www.ldancymru.org.uk/ 
http://www.mhrnc.org 
http://phirn.org.uk 
http://www.opanwales.org.uk 
http://wcrn.wales.nhs.uk 
58 KKS-Network Nat 19 public all diseases 74 publications between 2009 and 2014. http://www.kks-netzwerk.de/en/network.html 
59 SKIC Nat 8 private intensive care 4 ongoing studies. http://www.stichtingkinderik.nl 
60 NNI Nat 94 private neonatal diseases 
Collection of data from the centers of Neonatal Intensice Care 
Unit in Italy. 7 publications between 2011 and 2014. http://www.neonatalnet.org/doku.php 
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 7). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
61 N-CCLG Nat 25 private 
paediatric 
cancer 
diseases 
5 closed studies, 7 ongoing studies, newsletter and publications 
(not quantified). https://cclg.arithmostech.com/ 
62 NICRN Nat 
all 
hospitals 
of 
Northern 
Ireland 
public all diseases 
Studies of the Northern Ireland network are registered on the UK 
Clinical Research Network Portfolio Database. 
The UK Clinical Research Network Portfolio Database has 14251 
studies (closed and ongoing) since 2006. 
http://www.nicrn.hscni.net/ 
63 NORCRIN Nat 6 public all diseases 
2 observational prospective studies, guidance for medical 
research, web CRF, national procedures for clinical trials, 
advanced course in Good Clinical Practices, partner meetings 
and conferences. 
http://www.norcrin.no 
64 PEDDCReN Inter Not 
available private 
gastroenterolog
y, hepatology, 
nutrition 
It is being done an on-line survey across Europe (at the moment 
in the UK) to establish the interest, expertise and resources in 
conducting clinical trials in this area. 
https://www.ueg.eu/fileadmin/user_upload/document
s/Awards/LINK.Award.2012.PEDDCReN_November
%202013.pdf 
65 PENTA-ID Inter Not 
available private 
paediatric HIV 
and other 
infectious 
diseases 
3  ongoing clinical trials, 11  closed clinical trials. http://www.pentatrials.org 
66 CICPed Nat 15 private paediatric diseases The number of clinical trials was 109 in 2010 and 121 in 2011.  
http://cic-
pediatriques.com/index.php/objectifs/objectifs 
67 PIGS Nat 40 private 
paediatric 
infectious 
diseases 
16 publications, reccommendations and guidelines since 2004. http://www.pigs.ch/ 
68 PRINTO Inter 350 private 
paediatric 
rheumatic 
diseases 
6  ongoing projects, 10 closed projects, more than 100 papers 
between 1997 and 2013. The network elaborates proceedings 
and a newsletter. 
http://www.printo.it/index.asp 
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 8). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
69 PREPARE Inter 22 private 
infectious 
diseases 
outbreak  
Clinical trials and training are planned to start in 2014. Kickoff of 
this network was on 5-7 February 2014, an FP7 project. https://www.combacte.com/?q=node/115 
70 PREDIMED Nat 19 public nutrition 1 ongoing clinical trial. 674 publications between 2007 and 2011. http://www.unav.edu/departamento/preventiva/predi
med 
71 POLCRIN Nat 12 public all diseases Not available. No website available. 
72 PtCRIN Nat 15 public all diseases Not available. http://web.fcm.unl.pt/ptcrin 
73 REEM Nat 15 public multiple 
sclerosis Not available. http://www.reem.es 
74 RIC Nat 64 public heart diseases 936 publications, 34 patents, 509 projects and 117 courses.  http://www.redcardiovascular.com 
75 RICET Nat 20 public tropical diseases 110 publications between 2007 and 2012. http://www.ricet.es 
76 Red SAMID Nat 13 public neonatal diseases 8  ongoing clinical trials. http://www.redsamid.net 
77 RTICCC Nat 73 public oncology 11 clinical trials, 243 projects, 12 courses, 158 publications and 4 guides between 2003 and 2012. http://www.rticc.org 
78 RIPPS Nat 
(PERENE, 
19) 
(RMNMI, 
29) 
public paediatric diseases 3 studies (PERENE). http://www.ripps.eu/site/defaut/ 
79 ROCRIN Nat 6 public all diseases Not available. http://www.rocrin.umfcv.ro 
80 AGMT Nat 130 private oncology 22 ongoing clinical trials and 2 closed clinical trials. http://www.agmt.at 
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Table 3 – List of the European Clinical Networks: acronym, national versus international, number of members, public versus private, target disease, 
relevant activities and website address (cont. 9). 
 
Acronym Nat/ Inter Members Nature Target Relevant activities Website address 
81 SweCRIN Nat 40 public all diseases Not available. http://www.swecrin.se 
82 SCTO Nat 6 private all diseases 4 articles between 2011 and 2014. http://www.scto.ch/ 
83 SAKK Nat 22 private oncology 198 articles between 2008 and 2013. http://sakk.ch 
84 SPOG Nat 9 private 
paediatric 
cancer 
diseases 
57 ongoing clinical trials in 2012. 306 articles between 2006 and 
2013. http://www.spog.ch 
85 SwissPedN
et Nat 8 private 
paediatric 
diseases Not available. http://www.swisspednet.ch 
86 TARN Nat Not 
available public Trauma 
The network provides annual meeting and trainings. 86 
publications between 1992 and 2014. http://www.tarn.ac.uk 
87 UKCRN Nat 
all 
hospitals 
and 
primary 
care 
services in 
the UK 
public all diseases UK Clinical Research Network Portfolio Database has 14251 
studies (closed and ongoing) since 2006. http://public.ukcrn.org.uk 
88 UKPVG Nat 10 
 
private paediatirc 
vaccines Not available. http://www.ukpvg.org/ukpvg/internet/en/index.html 
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